Медицинская библиотека · Expert opinion on drug delivery · 2023

Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity.

Rahman Ziyaur, Khuroo Tahir, Mohamed Eman M, Dharani Sathish, Kayalar Canberk, Kuttolamadom Mathew A, Sangaré Lamba Omar, Khan Mansoor A

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

OBJECTIVES

The focus of the present research is to develop printlet formulations of pyrimethamine (PMT).

METHODS

Printlets formulation of PMT were developed by screening design by varying laser scanning speed, Kollidon® VA 64, polyvinylpyrrolidone, and disintegrant.

RESULTS

Laser scanning speed, Kollidon® VA, and disintegrant had statistically significant effect on hardness, disintegration time, and/or dissolution (p < 0.05). Dissolution was almost 100% in 30 min. X-ray powder diffraction indicated partial amorphous transformation of the crystalline drug. Pharmacokinetic and anti-toxoplasma activity profiles of the printlets and compressed tablets were superimposable with no statistical difference (p > 0.05).

CONCLUSION

Clinical performance of the printlets would be similar to the compressed tablets.

Для цитирования: Rahman Ziyaur, Khuroo Tahir, Mohamed Eman M, Dharani Sathish, Kayalar Canberk, Kuttolamadom Mathew A, Sangaré Lamba Omar, Khan Mansoor A. Pyrimethamine 3D printlets for pediatric toxoplasmosis: design, pharmacokinetics, and anti-toxoplasma activity.. Expert opinion on drug delivery. 2023. DOI: 10.1080/17425247.2023.2169272.

Предметные рубрики MeSH

Humans Child Pyrimethamine Povidone Toxoplasma Excipients Tablets Toxoplasmosis Solubility

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.